Feed / CAPR

Capricor Therapeutics, Inc.

CAPR

Healthcare · 8.31 -3.8% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Capricor Therapeutics, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.

Company-3.8% todayVolume comparison unavailable
Market group0 of 2 activeExosome Therapeutics & Commerce · unavailable
Disclosed network0 of 6 confirmingNo filing-linked name is confirming now
What would change this read
  • CAPR's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if CAPR's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • CAPR's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements35
Verified relationships6
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case
  • Latest annual revenue changed -100.0% year over year.
  • Diluted shares increased 32.0% in the latest annual period.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

8.31
6m-70.3%12m+32.9%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$244,898-21.1%$-0.87+48.3%
2022-12-31$2.6M+941.8%$-1.18+6.3%
2023-12-31$25.2M+886.8%$-0.83+9.1%
2024-12-31$22.3M-11.5%$-1.15+31.5%
2025-12-31$0-100.0%$-2.26+32.0%

What management says matters

Persistent and emerging business drivers

Foreign exchangemixed · 4 filings
Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in 2023 and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89.0 millio…
10-Q · May 13, 2026
Product pipeline and R&Dmixed · 4 filings
Upfront payments received in advance of performance are recorded as deferred revenue.
10-Q · May 13, 2026
Legal and regulatory exposuremixed · 3 filings
Subject to regulatory approval, Capricor will have the right to receive a share of product revenue which falls between 30 and 50 percent.
10-K · Mar 17, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales · EV/sales . Comparisons use only industry-matched filing peers.

Scenario scaffold

No usable price/earnings or price/sales multiple (need a fresh price).

Price action

How the market is pricing the story

8.31-3.8% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for CAPR. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for CAPR. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind CAPR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TMOThermo Fisher Scientific Inc.supplierMar 17, 2026

13 Table of Contents Cell Line License Agreement with Life Technologies On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of c…

OPYOppenheimer Holdings Inc.partnerNov 10, 2025

g under a prospectus supplement for aggregate sales proceeds of up to $150.0 million (the “September 2025 ATM Program”) on September 10, 2025, pursuant to an Equity Distribution Agreement with Piper Sandler and Oppenheimer (collectively, the “Agents”) by whic…

Depended on by

BCDABioCardia, Inc.competitorMar 24, 2026

The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Cel…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CAPR is currently a Leader in the organic co-movement group Exosome Therapeutics & Commerce. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for CAPR; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.